Search Result

Results for "

KRASG12D inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Drug Derivative (1) ERK (1) Ras (17)
By Research Areas:	Cancer (17)
Click Chemistry:	Alkynes (6)

Inhibitors & Agonists

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-171255

KRAS G12D inhibitor 26	Ras	Cancer
KRAS G12D inhibitor 26 is a modulator of Kras, targeting Kras(G12D) with an IC₅₀ ≤ 100 nM .

HY-157029S

KRASG12D-IN-1	Ras	Cancer
KRASG12D-IN-1 (compound 22) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-157031S

KRASG12D-IN-2	Ras	Cancer
KRASG12D-IN-2 (compound 28) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-163488

KRASG12D-IN-4	Ras	Cancer
KRASG12D-IN-4 (example 38) is a KRas ^G12D inhibitor with an IC₅₀ of 3.3 nM. KRASG12D-IN-4 inhibits proliferation of pancreatic cancer ASPC-1 cells with an IC₅₀ of 12 nM .

HY-174243

KRASG12D-IN-5	Ras	Cancer
KRASG12D-IN-5 (Compound 241) is an orally active *KRAS(G12D)* inhibitor with an IC₅₀ of 11 nM. KRASG12D-IN-5 has potent anticancer activity with no significant cytotoxicity against BxPC-3 (WT), KRAS mutation AsPC-1 (G12D) and MIAPaCa-2 cells (G12C) with CC₅₀s of 10.37, 0.76 and 0.3 μM, respectively. KRASG12D-IN-5 can be used for cancer research, such as lung, pancreatic and colorectal cancer .

HY-175529

KRASG12D-IN-7	Ras ERK Apoptosis	Cancer
KRASG12D-IN-7 is a selective KRAS ^G12D inhibitor. KRASG12D-IN-7 displays strong binding activity for KRAS ^G12D in both its GDP- and GTP- bound states, with K_d value of 1.12 nM and 1.86 nM, respectively. KRASG12D-IN-7 inhibits the proliferation of KRAS ^G12D harboring AsPC-1 cells with an IC₅₀ value of 10 nM and suppresses MAPK signaling. KRASG12D-IN-7 induces G0/G1 phase arrest and apoptosis in AsPC-1 cells, and strongly inhibits their colony formation. KRASG12D-IN-7 can be used for the study of cancers harboring KRAS ^G12D mutation, particularly pancreatic ductal adenocarcinoma (PDAC) .

HY-158007

(RS)-G12Di-1	Ras	Cancer
(RS)-G12Di-1 is a selective, covalent inhibitor of *K-Ras-G12D* .

HY-176419

KRAS inhibitor-42	Ras	Cancer
KRAS inhibitor-42 (compound 8) is a potent USP7 inhibitor. KRAS inhibitor-42 has high affinity against GDP-bound KRASG12D with a K_i of 2.7 μM .

HY-162445

KRASG12D-IN-3	Ras	Cancer
KRASG12D-IN-3 (compound Z1084) is an orally active KRAS ^G12D inhibitor that inhibits the cell growth of AGS and AsPC-1 cells with IC₅₀ values of 0.38 nM and 1.23 nM, respectively .

HY-176870

KRAS-IN-42	Ras	Cancer
KRAS-IN-42 (Compound Z1063) is a covalent KRAS ^G12D mutants inhibitor. KRAS-IN-42 is promising for research of KRASG12D-mutant cancers (e.g., non-small cell lung cancer, colorectal cancer) .

HY-159127

HRS-4642	Ras	Cancer
HRS-4642 is a selective *KRAS(G12D)* inhibitor (Kd=0.083 nM) with anti-cancer activity. HRS-4642 synergizes with Carfilzomib (HY-10455) and exhibits significant in vivo potency to reshape the tumor microenvironment into an immune-activating microenvironment.

HY-153663

TH-Z827	Ras	Cancer
TH-Z827 is a mutant selective *KRAS(G12D)* inhibitor with an IC₅₀ of 2.4 μM. TH-Z827 does not bind KRAS(WT) or KRAS(G12C). TH-Z827 blocked the KRAS(G12D)-CRAF interaction with an IC₅₀ value of 42 μM .

HY-173329

KRAS-IN-41	Ras	Cancer
KRAS-IN-41 is an inhibitor of KRAS with IC₅₀ values of <0.01 μM for KRAS G12D and KRAS G12V. KRAS-IN-41 inhibits RAS mutant cell lines, GP2D (KRAS-G12D) and SW620 (KRAS-G12V). KRAS-IN-41 can be used in cancer research .

HY-126247

BI-2852	Ras	Cancer
BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based agent design with nanomolar affinity. BI-2852 is mechanistically distinct from covalent KRASG12C inhibitor (binds to switch II pocket) and binds ten-fold more strongly to active KRASG12D versus KRASwt (740 nM vs 7.5 μM). BI-2852 blocks GEF, GAP, and effector interactions with KRAS, leading to inhibition of downstream signaling and an antiproliferative effect in KRAS mutant cells.

HY-134813A

MRTX1133 formic	Ras	Cancer
MRTX1133 formic is a noncovalent, potent, and selective KRAS G12D inhibitor. MRTX1133 formic optimally fills the switch II pocket and extends three substituents to favorably interact with the protein, resulting in an estimated K_D against KRAS G12D of 0.2 pM. MRTX1133 formic prevents SOS1-catalyzed nucleotide exchange and/or formation of the KRASG12D/GTP/RAF1 complex, thereby inhibiting mutant KRAS-dependent signal transduction. MRTX1133 formic shows efficacy in tumor models harboring KRAS G12D mutations .

HY-126247B

(R)-BI-2852	Drug Derivative Ras	Cancer
(R)-BI-2852 is the isomer of BI-2852 (HY-126247), and can be used as an experimental control. BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based agent design with nanomolar affinity. BI-2852 is mechanistically distinct from covalent KRASG12C inhibitor (binds to switch II pocket) and binds ten-fold more strongly to active KRASG12D versus KRASwt (740 nM vs 7.5 μM). BI-2852 blocks GEF, GAP, and effector interactions with KRAS, leading to inhibition of downstream signaling and an antiproliferative effect in KRAS mutant cells.

HY-173637

AZD0022	Ras	Cancer
AZD0022 is a selective and orally active KRAS ^G12D inhibitor. AZD0022 inhibits KRAS pathway suppression in the GP2D xenograft model .

Cat. No.	Product Name	Chemical Structure

HY-157029S

KRASG12D-IN-1
KRASG12D-IN-1 (compound 22) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-157031S

KRASG12D-IN-2
KRASG12D-IN-2 (compound 28) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

Cat. No.	Product Name		Classification

HY-157029S

KRASG12D-IN-1		Alkynes
KRASG12D-IN-1 (compound 22) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-157031S

KRASG12D-IN-2		Alkynes
KRASG12D-IN-2 (compound 28) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-173637

AZD0022		Alkynes
AZD0022 is a selective and orally active KRAS ^G12D inhibitor. AZD0022 inhibits KRAS pathway suppression in the GP2D xenograft model .

HY-163488

KRASG12D-IN-4		Alkynes
KRASG12D-IN-4 (example 38) is a KRas ^G12D inhibitor with an IC₅₀ of 3.3 nM. KRASG12D-IN-4 inhibits proliferation of pancreatic cancer ASPC-1 cells with an IC₅₀ of 12 nM .

HY-158007

(RS)-G12Di-1		Alkynes
(RS)-G12Di-1 is a selective, covalent inhibitor of *K-Ras-G12D* .

HY-176870

KRAS-IN-42		Alkynes
KRAS-IN-42 (Compound Z1063) is a covalent KRAS ^G12D mutants inhibitor. KRAS-IN-42 is promising for research of KRASG12D-mutant cancers (e.g., non-small cell lung cancer, colorectal cancer) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.